Drug Approval | July 22, 2024
Briefs: Zydus Lifesciences and Divi's Laboratories
Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets
Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets
Dyslipidemia is a critical risk factor for cardiovascular diseases
An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer
The consultative meet, a first of its kind, will bring together representatives from diverse domains of Traditional Medicine (TM) in India
Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas
Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date
The transaction aligns with Lupin's strategy to grow its global presence in Specialty areas
Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
Sales reflect continued strong growth in oncology and vaccines
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
